Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Safety

Mifepristone

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

The FDA describes an evidence‑driven study now in a data‑gathering phase with no projected timeline.

FDA Opens Mifepristone Safety Review as 20 States Vow to Defend Access

FDA Commissioner Pledges Safety Review of Abortion Pill Mifepristone